Type 2 Diabetes Pharmacoepidemiology Update 2014: Safety Versus Efficacy

Sonal Singh

Research output: Contribution to journalReview articlepeer-review


The number of available options for type 2 diabetes has increased steadily over the last decade. These include the insulins, metformin, sulfonylureas, thiazolidinediones, incretin-based therapies, and sodium-glucose cotransporter 2 inhibitors. In this paper, the safety and efficacy of these agents are reviewed with a view on updated findings that have emerged over the last few years. Most drugs for type 2 diabetes effectively lower glycated hemoglobin. Their efficacy is in the range of approximate 0.8–1.5 % reduction in glycated hemoglobin for most agents. No drug for type 2 diabetes has been shown to reduce cardiovascular risk in a clinical trial which represents a gap in the therapeutic armamentarium for type 2 diabetes. Recent evidence has linked the thiazolidinediones to bladder cancer and raised concerns about pancreatic cancer with incretins, which requires further confirmation. The rapidly emerging evidence in the field of pharmacoepidemiology of diabetes will continue to provide answers to important questions on safety and efficacy in 2015 and beyond.

Original languageEnglish (US)
Article number563
JournalCurrent diabetes reports
Issue number12
StatePublished - Oct 26 2014


  • Antidiabetic drugs
  • Efficacy
  • Pharmacoepidemiology
  • Safety

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Type 2 Diabetes Pharmacoepidemiology Update 2014: Safety Versus Efficacy'. Together they form a unique fingerprint.

Cite this